-
公开(公告)号：US20110305663A1
公开(公告)日：2011-12-15
申请号：US13098851
申请日：2011-05-02
申请人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
发明人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
IPC分类号： A61K38/20 , C07K19/00 , A61K38/17 , A61P3/10 , A61P3/04 , A61K38/18 , A61K38/28 , A61K38/22 , A61K38/26 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/21 , A61P3/00 , A61P3/06 , A61P9/00 , C07K14/47
CPC分类号： C12P21/005 , A61K38/00 , A61K47/62 , A61K47/643 , C07K14/435 , C07K14/50 , C07K14/575 , C07K14/78 , C07K2319/70 , C12N15/62
摘要： The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
摘要翻译： 本发明涉及基于结合血清白蛋白的第十纤连蛋白III型结构域（10Fn3）的抗体样蛋白。 本发明还涉及包含与用于诊断和治疗应用的异源蛋白质连接的血清白蛋白结合10Fn3的融合分子。
-
公开(公告)号：US08969289B2
公开(公告)日：2015-03-03
申请号：US13098851
申请日：2011-05-02
申请人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
发明人： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
CPC分类号： C12P21/005 , A61K38/00 , A61K47/62 , A61K47/643 , C07K14/435 , C07K14/50 , C07K14/575 , C07K14/78 , C07K2319/70 , C12N15/62
摘要： The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
摘要翻译： 本发明涉及基于结合血清白蛋白的第十纤连蛋白III型结构域（10Fn3）的抗体样蛋白。 本发明还涉及包含与用于诊断和治疗应用的异源蛋白质连接的血清白蛋白结合10Fn3的融合分子。
-
公开(公告)号：US08420098B2
公开(公告)日：2013-04-16
申请号：US13085864
申请日：2011-04-13
申请人： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
发明人： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC分类号： C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
摘要： The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
摘要翻译： 本发明涉及结合PCSK9的基于纤连蛋白的支架结构域蛋白。 本发明还涉及创新的蛋白质在治疗应用中用于治疗动脉粥样硬化，高胆固醇血症和其它胆固醇相关疾病的用途。 本发明还涉及包含这种蛋白质的细胞，编码这些蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
4.发明申请公开(公告)号：US20120094909A1
公开(公告)日：2012-04-19
申请号：US13085864
申请日：2011-04-13
申请人： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
发明人： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC分类号： C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
摘要： The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
摘要翻译： 本发明涉及结合PCSK9的基于纤连蛋白的支架结构域蛋白。 本发明还涉及创新的蛋白质在治疗应用中用于治疗动脉粥样硬化，高胆固醇血症和其它胆固醇相关疾病的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
5.发明授权Screen employing fluorescence anisotropy to identify compounds with affinity for nucleic acids 失效筛选采用荧光各向异性以鉴定对核酸具有亲和性的化合物公开(公告)号：US06331392B1
公开(公告)日：2001-12-18
申请号：US09060449
申请日：1998-03-05
IPC分类号： C12Q168
CPC分类号： C40B30/10 , C12N15/1048 , C12Q1/6811 , C12Q1/6813 , C12Q1/6816 , C40B40/06 , C40B50/06 , C12Q2561/119
摘要： The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.
摘要翻译： 本发明提供用于筛选生物活性化合物的方法，特别是结合涉及疾病发病机理或调节生理功能的RNA序列的方法。 所述方法包括在存在和不存在测试配体的情况下评估RNA靶标的稳定性和/或构象，以及鉴定导致靶RNA稳定性和/或构象可测量变化的任何测试配体。 在优选的实施方案中，通过测量荧光标记的探针的荧光偏振来评估配体对靶RNA稳定性和/或构象的影响。
-
公开(公告)号：US06335339B1
公开(公告)日：2002-01-01
申请号：US09229703
申请日：1999-01-13
IPC分类号： A61K3153
CPC分类号： A61K31/53
摘要： The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.
摘要翻译： 本发明提供包含1,3,5-三嗪衍生物的药物制剂。 本发明的化合物和制剂表现出一系列活性，包括抗病毒和抗生素活性，并且可以单独或组合使用制剂作为治疗需要抗病毒和/或抗生素治疗的患者的方法。 本发明的三嗪衍生物结合并抑制功能性核酸，因此在治疗与DNA和RNA病毒相关的病症方面具有广泛的适用性。
-
7.发明授权公开(公告)号：US06569628B2
公开(公告)日：2003-05-27
申请号：US09961008
申请日：2001-09-20
IPC分类号： C12Q168
CPC分类号： C40B30/10 , C12N15/1048 , C12Q1/6811 , C12Q1/6813 , C12Q1/6816 , C40B40/06 , C40B50/06 , C12Q2561/119
摘要： The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.047 秒)